Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — Shareholder Meeting (October 2021)
13 slides from Atomo Diagnostics's shareholder meeting presentation, Oct 28, 2021
Slide 1: Annual General Meeting - Managing Director's Presentation
Atomo Diagnostics Limited ACN 142 925 684 701 – 703 Parramatta Road Leichhardt NSW 2040 Australia For personal use only ANNUAL GENERAL MEETING Thursday 28 October 2021 Managing Director’s Presentation ATOMO ATOMO DIAGNOSTICS DIAGNOSTICS LIMITED|| (ASX: LIMITED (ASX: AT1) AT1)
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on communications transmitted or otherwise made available to the recipient in information available as at the date of this presentation. The information in this connection with the oppor
Slide 3: Atomo's Vision: Re-imagining Diagnostics
ATOMO’S VISION HIV Re-imagining Diagnostics For personal use only VISION MISSION VALUES Empowering people to Re-imagining diagnostics by Impact - Commercialising products that matter to our users enjoy healthier, more putting the user point of informed lives through care experience at the Innovation
Slide 4: Corporate Profile
CORPORATE PROFILE Key financial details Share price performance For personal use only ASX code AT1 Share price (27/10/21) $0.305 Shares on issue 568.6m Options on issue 23.7m Market cap* $173m Current cash (30/09/21) $15.2m *Undiluted Board Member Position Major Shareholders % (undiluted) John Keith
Slide 5: Key Highlights - FY21
KEY HIGHLIGHTS - FY21 For personal use only • Atomo COVID-19 rapid tests – Added by the TGA to the ARTG in H1 FY21 for supply in Australia. Tests launched in Q2 & Q3 FY21. Circa. 50k, primarily antibody test units sold in 2H FY21. • Regulatory Approval – Atomo devices have now achieved broad regulat
Slide 6: FY21 Summary Financials
FY21 SUMMARY FINANCIALS For personal use only AUD FY21 FY20 Variance Sales ($m) 6.72 5.37 25% Gross Margin ($m) 3.42 3.19 7% GP margin (%) 51% 60% EBITDA ($m) (4.79) (2.38) (101%) Sales Revenue Split by Product 30% 54% 16% COVID-19 HIV Other OEM ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 6
Slide 7: Strategic Focus
STRATEGIC FOCUS HIV For personal use only Capabilities Innovation, Co-development & Commercialisation (device design, regulatory, usability, e-health, IP) Markets Infectious Rapid Test Consumer Health Diseases Tests Devices & Wellness (HIV, COVID, Others) (devices, components) (entering new markets)
Slide 8: Atomo's Core Capabilities
ATOMO’S CORE CAPABILITIES The intersection between Medical Devices & User-friendly Diagnostics For personal use only IP Intensive Less IP Intensive More sales focused Atomo DNA Core Functionality Devices Finished Product Customer Delivery Point-of-Care Self Testing • Blood collection • Galileo • HIV
Slide 9: Products and Customers
PRODUCTS AND CUSTOMERS For personal use only PRODUCTS CUSTOMERS/ CHANNELS HIV- Self Test and Professional Iyeza, Owen Mumford (UK/EU) Infectious Mylan/Viatris (LMIC), Australia - Distributors Diseases Tests (HIV, COVID, Others) COVID- Antigen and Antibody Atomo branded Antigen tests (Australia) OEM
Slide 10: Atomo's Infectious Disease Business
Market ATOMO’S INFECTIOUS DISEASE BUSINESS HIV For personal use only HIV COVID-19 COVID Antigen - Australia Atomo has an opportunity to sell up to 20 million antigen tests during FY22 & 23. COVID OEM Devices With extended market life, we see some opportunity to supply custom cassettes to leading COV
Slide 11: Co-Development Business
CO-DEVELOPMENT BUSINESS For personal use only GOAL: To become the leading provider of integrated Rapid test devices by leveraging Atomo’s capabilities, IP and know-how by offering Co-Development partners access to Atomo’s platforms and proprietary components Accelerate roll-out of current technologi
Slide 12: Telehealth: Opening New Markets for Atomo
TELEHEALTH: OPENING NEW MARKETS FOR ATOMO COVID-19 has accelerated personalised, predictive and preventive medicine programs For personal use only • • Consumer adoption and growth in Telehealth, POCT, OTC and at-home self-testing markets • Telehealth consultations 38x higher than before the pandemic
Slide 13: Priorities for FY22
PRIORITIES FOR FY22* For personal use only Capitalising on local COVID-19 opportunities, including launch of a self-test product (subject to TGA approval), and increasing resources to support growing demand across public health and private sector channels Progressing strategic partnership opportunit
Atomo Diagnostics — Shareholder Meeting (October 2021) on 6ix